CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exchanging cases and sharing knowledge. During the first 18
Tag: pathology network
CEO SUMMARY: Digital pathology holds the promise of interconnecting pathologists around the globe in ways that advance diagnostic accuracy and improve patient outcomes. One pioneering digital pathology collaboration involves the pathology departments at the medical schools of the University of California, Los Angeles (UCLA) and Zhejiang University in Hangzhou, China.
PART ONE OF A SERIES
IT IS TOUGH TIMES FINANCIALLY for pathology and clinical laboratories in the British Isles. In both the nations of the United Kingdom and Ireland, the budget woes of the respective national governments are driving major changes in the organization and delivery of laboratory testing services.
In the United Kingdom, efforts by the government dating back to
CEO Summary: In the second installment of our exclusive two- part interview, the executive directors of two regional laboratory networks formed in the 1990s (one in Michigan and one in Washington State) share their assessment of why their respective lab networks have performed strongly over the past two decades. They also identify the reasons why
MOST PEOPLE KNOWLEDGEABLE ABOUT THE INNER WORKINGS of the clinical laboratory industry generally agree that hospital laboratories possess inherent advantages over commercial laboratories—anytime a hospital lab outreach program is organized properly and marketed professionally.
Certainly the managed care contracting success of Joint Venture Hospital Laboratories (JVHL) in Detroit and throughout the state of Michigan bears testimony
CEO SUMMARY: It’s time again to recognize and honor the lab industry’s strong leaders in innovative management. These laboratory executives are implementing business strategies designed to position their lab organizations to serve the changing needs of the healthcare system. Their vision and willingness to “stay the course” are traits they hold in common.
IT’S BEEN FIVE
CEO SUMMARY: After a lot of money and much effort, the fledgling crop of companies wanting to consolidate and manage pathology group practices has narrowed into just two market leaders: AmeriPath and Pathology Service Associates. These two companies could not be more different in their goals and operating philosophies. For local pathology groups, this is
This section of the White Paper deals with the marketplace for laboratory services. For brevity and clarity, I will address five components: 1) independent commercial laboratories; 2) hospital-based laboratories; 3) esoteric, reference, and specialty testing laboratories; 4) anatomic pathology lab- oratories; and 5) diagnostics manufacturers and suppliers.
These groups represent the basic divisions within the competitive
CEO SUMMARY: It’s not just the Medicare program that wants to eat away at the reimbursement for laboratory tests. Private payers continue to seek ways to cut back reimbursement to laboratory providers. The latest attack is on two surgical pathology codes—88300 and 88302. In at least three states, Humana Healthcare Corporation has denied claims submitted
CEO SUMMARY: Although the financial travails of the physician practice management (PPM) industry are widely known, there is little recognition that a number of single-specialty PPMs are doing well. This is true of pathology, where at least six pathology-based PPMs still remain in business. The best of them demonstrate strong revenue growth and good profits.